The estimated Net Worth of Alan Charles Moses is at least $4.95 mil dollars as of 28 July 2021. Alan Moses owns over 5,000 units of BiomX Inc stock worth over $4,950 and over the last 4 years he sold PHGE stock worth over $0. In addition, he makes $0 as Independent Director at BiomX Inc.
Alan has made over 1 trades of the BiomX Inc stock since 2021, according to the Form 4 filled with the SEC. Most recently he bought 5,000 units of PHGE stock worth $20,000 on 28 July 2021.
The largest trade he's ever made was buying 5,000 units of BiomX Inc stock on 28 July 2021 worth over $20,000. On average, Alan trades about 833 units every 0 days since 2020. As of 28 July 2021 he still owns at least 5,000 units of BiomX Inc stock.
You can see the complete history of Alan Moses stock trades at the bottom of the page.
Dr. Alan C. Moses M.D. serves as Independent Director of the Company. He served as the Global Chief Medical Officer of Novo Nordisk A/S from 2013 until his retirement in 2018. Prior to that he served in various roles at Novo Nordisk A/S since 2004 beginning as Associate Vice President of Medical Affairs in the United States. Throughout his career, Dr. Moses has specialized in developing novel therapeutics and diagnostics for diabetes mellitus. He co-founded and directed the Clinical Investigator Training Program at Beth Israel Deaconess-Harvard Medical School-MIT. From 1998 to 2004, Dr. Moses served as Senior Vice President and Chief Medical Officer of the Joslin Diabetes Center with specific responsibility for the Joslin Clinic. Dr. Moses earned his MD from the Washington University School of Medicine in St. Louis, worked for three years at the National Institutes of Health, completed his clinical endocrine/diabetes training at Tufts New England Medical Center, and studied Health Care Strategy at Harvard Business School.
Alan Moses is 72, he's been the Independent Director of BiomX Inc since 2020. There are no older and 13 younger executives at BiomX Inc.
Alan's mailing address filed with the SEC is C/O BIOMX INC., 22 EINSTEIN ST., FLOOR 4, , NESS ZIONA,, L3, 7414003.
Over the last 5 years, insiders at BiomX Inc have traded over $332,366 worth of BiomX Inc stock and bought 1,036,414 units worth $787,614 . The most active insiders traders include James Edeerfield Management..., Chidozie Ugwumba, eErez Chimovits. On average, BiomX Inc executives and independent directors trade stock every 68 days with the average trade being worth of $533,749. The most recent stock trade was executed by James Edeerfield Management... on 15 July 2024, trading 11,766,000 units of PHGE stock currently worth $11,648,340.
biomx is a microbiome drug discovery company developing customized phage therapies that target and destroy harmful bacteria in chronic diseases such as inflammatory bowel disease (ibd) and cancer. we discover and validate proprietary bacterial targets and customize our natural and engineered phage compositions against these targets. the company’s platforms use computational and synthetic biology and cutting-edge research from profs. rotem sorek, ph.d., eran elinav, m.d., ph.d., and eran segal, ph.d., of the weizmann institute of science; and professor timothy k. lu, m.d., ph.d., of the massachusetts institute of technology. investors in the company include orbimed israel incubator lp, johnson & johnson development corporation inc., takeda ventures, inc., seventure partners, mirae asset global investments, and sbi.
BiomX Inc executives and other stock owners filed with the SEC include: